Ryan Deschner
Stock Analyst at Raymond James
(4.51)
# 1,064
Out of 5,043 analysts
72
Total ratings
50.8%
Success rate
25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Reiterated: Buy | $106 → $53 | $27.38 | +93.57% | 14 | Oct 1, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | n/a | $29.88 | - | 8 | Sep 15, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $27 → $40 | $13.19 | +203.26% | 6 | Aug 7, 2026 | |
| ACOG Alpha Cognition | Initiated Coverage: Buy | $20 | $9.04 | +121.24% | 1 | Jul 10, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $10 | $1.03 | +870.87% | 5 | Jul 8, 2026 | |
| ACHV Achieve Life Sciences | Initiated Coverage: Buy | $20 | $7.41 | +169.91% | 1 | Jun 26, 2026 | |
| PRQR ProQR Therapeutics | Reiterated: Buy | $14 → $10 | $1.63 | +513.50% | 2 | Jun 26, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | n/a | $28.51 | - | 2 | Jun 24, 2026 | |
| DNTH Dianthus Therapeutics | Reiterated: Buy | n/a | $82.37 | - | 5 | Jun 12, 2026 | |
| ADMA ADMA Biologics | Initiated Coverage: Buy | $21 | $10.36 | +102.70% | 1 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.60 | +462.50% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $110 → $165 | $86.01 | +91.84% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $23 | $10.16 | +126.38% | 2 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.23 | - | 11 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $54 → $143 | $138.77 | +3.05% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $12 | $3.28 | n/a | 4 | Aug 5, 2025 |
Liquidia
Oct 1, 2026
Reiterated: Buy
Price Target: $106 → $53
Current: $27.38
Upside: +93.57%
Vera Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $29.88
Upside: -
Trevi Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $27 → $40
Current: $13.19
Upside: +203.26%
Alpha Cognition
Jul 10, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $9.04
Upside: +121.24%
Tvardi Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $10
Current: $1.03
Upside: +870.87%
Achieve Life Sciences
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $7.41
Upside: +169.91%
ProQR Therapeutics
Jun 26, 2026
Reiterated: Buy
Price Target: $14 → $10
Current: $1.63
Upside: +513.50%
Viking Therapeutics
Jun 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $28.51
Upside: -
Dianthus Therapeutics
Jun 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $82.37
Upside: -
ADMA Biologics
Jun 10, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $10.36
Upside: +102.70%
May 13, 2026
Reiterated: Buy
Price Target: $9
Current: $1.60
Upside: +462.50%
May 7, 2026
Reiterated: Buy
Price Target: $110 → $165
Current: $86.01
Upside: +91.84%
Mar 13, 2026
Upgraded: Buy
Price Target: $23
Current: $10.16
Upside: +126.38%
Jan 9, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.23
Upside: -
Nov 19, 2025
Upgraded: Buy
Price Target: $54 → $143
Current: $138.77
Upside: +3.05%
Aug 5, 2025
Reiterated: Buy
Price Target: $11 → $12
Current: $3.28
Upside: n/a